ENDPOINTS NEWS5h
Hims eyes growth in its weight loss busi­ness, de­spite end of semaglu­tide short­age
Hims & Hers expects revenue from its weight loss business to soar in 2025, even though a recent FDA move could make it ...
WCPO Cincinnati3h
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor
With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears ...
Hosted on MSN16h
Hims & Hers Stock Sinks After-Hours As Weight-Loss Roadmap Gets Clouded — Retail Pounces On The Dip
Hims & Hers Health Inc. shares plunged over 18% in after-hours trading on Monday after the telehealth company reported strong ...
Modern Healthcare20h
Hims & Hers pivots as semaglutide shortage ends
Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...
Hims & Hers Shares Sink Despite Upbeat Earnings, Outlook
Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...
Axios on MSN3d
Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...
Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...